Literature DB >> 15766602

Studies of the paradoxical effect of caspofungin at high drug concentrations.

David A Stevens1, Theodore C White, David S Perlin, Claude P Selitrennikoff.   

Abstract

Turbid growth of some Candida albicans isolates occurs, paradoxically, in some high concentrations of caspofungin, above the minimum inhibitory concentration. We show that the resistant phenotype is first detectable after 24 h of drug exposure. Although other studies have suggested an association between some azole resistance mechanisms and caspofungin resistance, our studies with isolates susceptible and resistant to azoles (the latter including groups with defined resistance mechanisms and derived mutants) suggest a weak association at most with a paradoxical effect. The paradoxical growth is not related to mutations in resistance-associated regions of the (1,3)-beta-glucan synthase complex and is not related to an up-regulation of (1,3)-beta-glucan synthase activity in the presence of drug. Subculture of a minority of tubes above the minimum fungicidal concentration yielded a few viable cells, suggesting random distribution, in some strains, of a few cells with propensity to grow in the presence of drug. We postulate high drug concentrations derepress or activate an as-yet undefined resistance mechanism(s).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15766602     DOI: 10.1016/j.diagmicrobio.2004.10.006

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  47 in total

1.  Evaluating retinal toxicity of intravitreal caspofungin in the mouse eye.

Authors:  Deb K Mojumder; Francis A Concepcion; Shil K Patel; Andrew J Barkmeier; Petros E Carvounis; John H Wilson; Eric R Holz; Theodore G Wensel
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-05-26       Impact factor: 4.799

2.  Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin.

Authors:  David A Stevens; Masayuki Ichinomiya; Yukako Koshi; Hiroyuki Horiuchi
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

3.  Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro.

Authors:  Mette D Jacobsen; Julie A Whyte; Frank C Odds
Journal:  Antimicrob Agents Chemother       Date:  2007-02-16       Impact factor: 5.191

4.  Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1.

Authors:  Sergey V Balashov; Steven Park; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

5.  Frequency of paradoxical effect with caspofungin in Candida albicans.

Authors:  D A Stevens
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-01-08       Impact factor: 3.267

6.  Characterization of caspofungin susceptibilities by broth and agar in Candida albicans clinical isolates with characterized mechanisms of azole resistance.

Authors:  Peter M Silver; Brian G Oliver; Theodore C White
Journal:  Med Mycol       Date:  2008-05       Impact factor: 4.076

7.  Trailing or paradoxical growth of Candida albicans when exposed to caspofungin is not associated with microsatellite genotypes.

Authors:  Mohamed Khlif; Hervé Bogreau; Annie Michel-Nguyen; Ali Ayadi; Stéphane Ranque
Journal:  Antimicrob Agents Chemother       Date:  2010-01-11       Impact factor: 5.191

Review 8.  Resistance to echinocandin-class antifungal drugs.

Authors:  David S Perlin
Journal:  Drug Resist Updat       Date:  2007-06-13       Impact factor: 18.500

Review 9.  Caspofungin: in pediatric patients with fungal infections.

Authors:  Karly P Garnock-Jones; Susan J Keam
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

Review 10.  Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients.

Authors:  Natalie J Carter; Gillian M Keating
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.